Investor Relations
Building a Healthier
Future Together
At Vactech, we are driven by a clear mission: to develop groundbreaking preventive solutions for type 1 diabetes and other autoimmune and infectious diseases. Our innovative vaccine pipeline, strong intellectual property portfolio, and global research partnerships place us at the forefront of transformative healthcare innovation.
Creating Lasting Health Impact Worldwide
Scientific Excellence with a Flexible and Efficient Operating Model
As a privately held biotechnology company, Vactech combines scientific excellence with a flexible and efficient operating model. Our progress is backed by a proven track record of academic and industrial collaborations, robust preclinical and clinical data, and a passionate leadership team committed to creating lasting health impact worldwide.
We invite investors and partners to join us on this journey as we advance our programs through critical clinical milestones and explore new commercial opportunities. Together, we have the opportunity to shape the future of preventive medicine.
Why Invest in Vactech
- First-in-class vaccine candidates with blockbuster potential
- Strong international patent portfolio covering vaccines, antivirals, and diagnostics
- Strategic collaborations with leading pharmaceutical and biotech companies
- Experienced leadership and world-renowned scientific founders
- Focused pipeline addressing significant unmet medical needs
For more information or to explore partnership opportunities, please contact our Investor Relations team.